Rodyti trumpą aprašą

dc.contributor.authorRembiałkowska, Nina,
dc.contributor.authorNovickij, Vitalij,
dc.contributor.authorRadzevičiūtė-Valčiukė, Eivina,
dc.contributor.authorMickevičiūtė, Eglė,
dc.contributor.authorGajewska-Naryniecka, Agnieszka,
dc.contributor.authorKulbacka, Julita,
dc.date.accessioned2023-12-22T07:06:33Z
dc.date.available2023-12-22T07:06:33Z
dc.date.issued2023.
dc.identifier.issn0378-5173
dc.identifier.other(crossref_id)153694733
dc.identifier.urihttps://etalpykla.vilniustech.lt/xmlui/handle/123456789/153724
dc.description.abstractElectrochemotherapy (ECT) involves combining anticancer drugs with electroporation, which is induced by pulsed electric fields (PEFs), while the effects vary in effectiveness based on the specific parameters of the electrical pulses and susceptibility of the cells to a specific drug. In this work, we utilized conventional microsecond electroporation protocols (0.8 – 1.5 kV/cm × 100 μs × 8, 1 Hz) and the new modality of nanosecond pulses (4 and 8 kV/cm × 500 ns × 100, 1 kHz and 1 MHz), which are compressed into a high frequency burst. Sensitive and resistant lung, breast and ovarian human cancer cell lines were used in the study. In order to overcome drug-resistance, we have investigated the feasibility to use anticancer drug cocktails i.e., bleomycin and cisplatin combinations with metformin, vinorelbine and Dp44mT. The different susceptibility of various human cancer cells lines to electric pulses was determined, the efficacy of ECT was characterized and the type of cell death depending on the combinations of drugs was investigated. The results indicate that synergistic effects of PEFs with drug cocktails may be used to overcome drug-resistance in cancer, while the application of nsPEF provides more flexibility in parametric protocols and modulation of cancer cell death.eng
dc.formatPDF
dc.format.extentp. 1-10.
dc.format.mediumtekstas / txt
dc.language.isoeng
dc.relation.isreferencedbyScience Citation Index Expanded (Web of Science)
dc.relation.isreferencedbyScopus
dc.relation.isreferencedbyScienceDirect
dc.relation.isreferencedbyPubMed
dc.source.urihttps://www.sciencedirect.com/science/article/pii/S0378517323009067
dc.titleSusceptibility of various human cancer cell lines to nanosecond and microsecond range electrochemotherapy: Feasibility of multi-drug cocktails /
dc.typeStraipsnis Web of Science DB / Article in Web of Science DB
dcterms.references53
dc.type.pubtypeS1 - Straipsnis Web of Science DB / Web of Science DB article
dc.contributor.institutionWroclaw Medical University
dc.contributor.institutionVilniaus Gedimino technikos universitetas Valstybinis mokslinių tyrimų institutas Inovatyvios medicinos centras
dc.contributor.institutionValstybinis mokslinių tyrimų institutas Inovatyvios medicinos centras
dc.contributor.institutionWroclaw Medical University Valstybinis mokslinių tyrimų institutas Inovatyvios medicinos centras
dc.contributor.facultyElektronikos fakultetas / Faculty of Electronics
dc.subject.researchfieldT 001 - Elektros ir elektronikos inžinerija / Electrical and electronic engineering
dc.subject.researchfieldN 010 - Biologija / Biology
dc.subject.vgtuprioritizedfieldsFM0202 - Ląstelių ir jų biologiškai aktyvių komponentų tyrimai / Investigations on cells and their biologically active components
dc.subject.ltspecializationsL105 - Sveikatos technologijos ir biotechnologijos / Health technologies and biotechnologies
dc.subject.endrug resistance
dc.subject.encancer cell lines
dc.subject.enmulti-drug cocktails
dc.subject.enpulsed electric field
dc.subject.enhigh-frequency nanosecond pulses
dc.subject.enelectrochemotherapy
dcterms.sourcetitleInternational journal of pharmaceutics.
dc.description.volumevol. 646
dc.publisher.nameElsevier
dc.publisher.cityAmsterdam
dc.identifier.doi153694733
dc.identifier.doi1-s2.0-S0378517323009067
dc.identifier.doiS0378-5173(23)00906-7
dc.identifier.doi85173480182
dc.identifier.doi2-s2.0-85173480182
dc.identifier.doi0
dc.identifier.doiS0378517323009067
dc.identifier.doi37802257
dc.identifier.doi001097643700001
dc.identifier.doi10.1016/j.ijpharm.2023.123485
dc.identifier.elaba179897225


Šio įrašo failai

FailaiDydisFormatasPeržiūra

Su šiuo įrašu susijusių failų nėra.

Šis įrašas yra šioje (-se) kolekcijoje (-ose)

Rodyti trumpą aprašą